XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenues (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Three months ended June 30, |  |  |  |  |  |  |  |  |  |
|  | 2020 |  |  |  |  |  | 2019 |  |  |  |
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 1,213 |  |  | $ | 33 |  |  | $ | 1,246 |  |  | $ | 1,315 |  |  | $ | 48 |  |  | $ | 1,363 |
Prolia® (denosumab) |  | 441 |  |  | 218 |  |  | 659 |  |  | 458 |  |  | 240 |  |  | 698 |
Neulasta® (pegfilgrastim) |  | 520 |  |  | 73 |  |  | 593 |  |  | 719 |  |  | 105 |  |  | 824 |
Otezla® (apremilast) |  | 464 |  |  | 97 |  |  | 561 |  |  | — |  |  | — |  |  | — |
XGEVA® (denosumab) |  | 318 |  |  | 117 |  |  | 435 |  |  | 379 |  |  | 120 |  |  | 499 |
Aranesp® (darbepoetin alfa) |  | 156 |  |  | 231 |  |  | 387 |  |  | 192 |  |  | 244 |  |  | 436 |
KYPROLIS® (carfilzomib) |  | 167 |  |  | 86 |  |  | 253 |  |  | 166 |  |  | 101 |  |  | 267 |
Repatha® (evolocumab) |  | 115 |  |  | 85 |  |  | 200 |  |  | 91 |  |  | 61 |  |  | 152 |
Other products |  | 1,034 |  |  | 540 |  |  | 1,574 |  |  | 822 |  |  | 513 |  |  | 1,335 |
Total product sales(1) |  | $ | 4,428 |  |  | $ | 1,480 |  |  | 5,908 |  |  | $ | 4,142 |  |  | $ | 1,432 |  |  | 5,574 |
Other revenues |  |  |  |  |  | 298 |  |  |  |  |  |  | 297 |
Total revenues |  |  |  |  |  | $ | 6,206 |  |  |  |  |  |  | $ | 5,871 |
|  | Six months ended June 30, |  |  |  |  |  |  |  |  |  |
|  | 2020 |  |  |  |  |  | 2019 |  |  |  |
|  | US |  | ROW |  | Total |  | US |  | ROW |  | Total
ENBREL |  | $ | 2,330 |  |  | $ | 69 |  |  | $ | 2,399 |  |  | $ | 2,421 |  |  | $ | 93 |  |  | $ | 2,514 |
Prolia® |  | 863 |  |  | 450 |  |  | 1,313 |  |  | 848 |  |  | 442 |  |  | 1,290 |
Neulasta® |  | 1,054 |  |  | 148 |  |  | 1,202 |  |  | 1,612 |  |  | 233 |  |  | 1,845 |
Otezla® |  | 841 |  |  | 199 |  |  | 1,040 |  |  | — |  |  | — |  |  | — |
XGEVA® |  | 673 |  |  | 243 |  |  | 916 |  |  | 735 |  |  | 235 |  |  | 970 |
Aranesp® |  | 331 |  |  | 478 |  |  | 809 |  |  | 374 |  |  | 476 |  |  | 850 |
KYPROLIS® |  | 354 |  |  | 179 |  |  | 533 |  |  | 320 |  |  | 192 |  |  | 512 |
Repatha® |  | 239 |  |  | 190 |  |  | 429 |  |  | 174 |  |  | 119 |  |  | 293 |
Other products |  | 2,022 |  |  | 1,139 |  |  | 3,161 |  |  | 1,649 |  |  | 937 |  |  | 2,586 |
Total product sales(1) |  | $ | 8,707 |  |  | $ | 3,095 |  |  | 11,802 |  |  | $ | 8,133 |  |  | $ | 2,727 |  |  | 10,860 |
Other revenues |  |  |  |  |  | 565 |  |  |  |  |  |  | 568 |
Total revenues |  |  |  |  |  | $ | 12,367 |  |  |  |  |  |  | $ | 11,428 |
____________ (1) Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2020 and 2019.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration